Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer?

International Journal of Hyperthermia

Volumn 26, Issue 3, 2010, Pages 232-246

  Lee, Chen Ting ^a   MacE, Thomas ^a   Repasky, Elizabeth A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anti tumour immunity; Hyperthermia; Hypoxia; Thermoregulation; Tumour microenvironment

Indexed keywords

CISPLATIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITROIMIDAZOLE; PACLITAXEL; PROTEIN P53; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL HYPOXIA; CELL MATURATION; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MICROENVIRONMENT; NEOPLASM; NONHUMAN; OVARY CANCER; OXYGEN TENSION; PROGNOSIS; REVIEW; T LYMPHOCYTE;

ANOXIA; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOSUPPRESSION; MICROCIRCULATION; NEOPLASMS;

EID: 77951134669     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656731003601745     Document Type: Review

References (127)

1. Corry PM, Dewhirst MW. Thermal medicine, heat shock proteins and cancer. Int J Hyperthermia 2005;21:675-677.
2. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995;345:540-543.
3. Sugimachi K, Kitamura K, Baba K, Ikebe M, Morita M, Matsuda H, Kuwano H. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus - A prospective randomized trial. Int J Hyperthermia 1992;8:289-295.
4. Sugimachi K, Kuwano H, Ide H, Toge T, Saku M, Oshiumi Y. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: A prospective randomized trial. Int J Hyperthermia 1994;10:485-493.
5. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994;28:163-169.
6. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119-11125.
7. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:287-295.
8. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, van Putten WL, van Rhoon GC, van Dijk JD, Gonzalez Gonzalez D, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731-744.
9. Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079-3085.
10. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-549.
11. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-437.
12. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. Oncologist 2008;13:S21-S26.
13. Kudo T, Ueda M, Kuge Y, Mukai T, Tanaka S, Masutani M, Kiyono Y, Kizaka-Kondoh S, Hiraoka M, Saji H. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med 2009;50:942-949.
14. 2 histography. In: Vaupel PW, Kelleher DK, Gunderoth M, editors. Tumor oxygenation. Stuttgart: Fischer; 1995. pp 219-232.
15. Minn H, Gronroos TJ, Komar G, Eskola O, Lehtio K, Tuomela J, Seppanen M, Solin O. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008;14:2932-2942.
16. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-239.
17. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
18. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50. (Pubitemid 23063609)
19. Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumorstromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007;14:2600-2607.
20. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
21. 2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 2002;60:634-639.
22. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 2001;18:243-259.
23. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: Prognostic and therapeutic implications. Cell Mol Life Sci 2007;64:3233-3247.
24. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
25. Alqawi O, Wang HP, Espiritu M, Singh G. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res 2007;41:788-797.
26. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008;110:465-475.
27. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
28. Nilsson I, Shibuya M, Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004;299:476-485.
29. Vaupel P, Kelleher DK, Thews O. Modulation of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;42:843-848.
30. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-5528.
31. Dewhirst MW, Ong ET, Klitzman B, Secomb TW, Vinuya RZ, Dodge R, Brizel D, Gross JF. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat Res 1992;130:171-182.
32. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-592.
33. Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006;66:1033-1039.
34. Teicher BA. Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol 2009;77:1665-1673.
35. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer 2008;44:2766-2773.
36. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8: 790-797.
37. Durand RE. Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991;20:253-258.
38. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-1198.
39. Jain RK. Physiological resistance to the treatment of solid tumors. In: Teicher BA, editor. Drug Resistance in Oncology. New York: Dekker; 1993. pp 87-105.
40. Song CW. Effect of local hyperthermia on blood flow and microenvironment: A review. Cancer Res 1984;44: S4721-S4730.
41. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49: 4373-4384.
42. Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990;50:3339-3344.
43. Vaupel PW. Oxygenation of solid tumors. In: Teicher BA, editor. Drug Resistance in Oncology. New York: Dekker; 1993. pp 53-85.
44. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-1468
45. Evans NTS, Naylor PFD. The effect of oxygen breathing and radiotherapy upon tissue oxygen tension of some human tumors. Br J Radiol 1963;36:418-425.
46. Wan J, Ma J, Mei J, Shan G. The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res 2009;28:150.
47. Ioannou M, Papamichali R, Kouvaras E, Mylonis I, Vageli D, Kerenidou T, Barbanis S, Daponte A, Simos G, Gourgoulianis K, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 2009;187:321-329.
48. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009;12:74-80.
49. Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, Shinomiya K, Hiraoka M. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009;100:747-757.
50. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009;125: 2198-2204.
51. Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C. Hypoxia-induced decrease in p53 protein level and increase in c-Jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia 2009;11:976-986.
52. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, et al. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxiainducible factor 1alpha. J Cancer Res Clin Oncol 2010;136:447-456.
53. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008;27:5944-5958.
54. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C. NKG2D ligands: Key targets of the immune response. Trends Immunol 2008;29:397-403.
55. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996;93:12445-12450.
56. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285: 727-729.
57. Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006;298:121-138.
58. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738.
59. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003;171:6891-6899.
60. Frederiksen LJ, Sullivan R, Maxwell LR, Macdonald- Goodfellow SK, Adams MA, Bennett BM, Siemens DR, Graham CH. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007;13:2199-2206.
61. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001;93:1879-1885.
62. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, Graham CH. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: Role of nitric oxide. Cancer Res 2008;68:4746-4753.
63. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003;3:984-993.
64. Moser M, Murphy KM. Dendritic cell regulation of TH1- TH2 development. Nat Immunol 2000;1:199-205.
65. Moser M. Regulation of Th1/Th2 development by antigenpresenting cells in vivo. Immunobiology 2001;204:551-557.
66. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 2000;89:2646-2654.
67. Yang M, Ma C, Liu S, Sun J, Shao Q, Gao W, Zhang Y, Li Z, Xie Q, Dong Z, et al. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology 2009;128:eS237-S249.
68. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:365-371.
69. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, Girolomononi G, Norgauer J. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003;101:3985-3990.
70. Westermann J, Bode U. Distribution of activated T cells migrating through the body: A matter of life and death. Immunol Today 1999;20:302-306.
71. 2 homeostasis. Curr Opin Genet Dev 1998;8:588-594.
72. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12: 149-162.
73. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-845.
74. Zuckerberg AL, Goldberg LI, Lederman HM. Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med 1994;22:197-203.
75. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S. Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med 1984;160: 369-385.
76. Lewis RS, Cahalan MD. Potassium and calcium channels in lymphocytes. Annu Rev Immunol 1995;13:623-653.
77. Conforti L, Petrovic M, Mohammad D, Lee S, Ma Q, Barone S, et al. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: A possible role in T cell proliferation. J Immunol 2003;170:695-702.
78. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, Sitkovsky MV. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001;167: 6140-6149.
79. Kim H, Peng G, Hicks JM, Weiss HL, Van Meir EG, Brenner MK, Yotnda P. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther 2008;16:599-606.
80. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-787.
81. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP. Ecto-50-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002;110:993-1002.
82. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-682.
83. Sitkovsky MV. T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009;30:102-108.
84. + regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008;38:2412-2418.
85. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor- induced Foxp3 gene expression: A role for DNA methylation. J Exp Med 2007;204:1543-1551.
86. Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest 1982;70: 550-557.
87. Aller MA, Arias JL, Sanchez-Patan F, Arias J. The inflammatory response: An efficient way of life. Med Sci Monit 2006;12:RA225-RA234.
88. Kawaguchi T, Veech RL, Uyeda K. Regulation of energy metabolism in macrophages during hypoxia. Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate. J Biol Chem 2001;276:28554-28561.
89. Fossati G, Moulding DA, Spiller DG, Moots RJ, White MR, Edwards SW. The mitochondrial network of human neutrophils: Role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol 2003;170:1964-1972.
90. Roiniotis J, Dinh H, Masendycz P, Turner A, Elsegood CL, Scholz GM, Hamilton JA. Hypoxia prolongs monocyte/ macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions. J Immunol 2009;182:7974-7981.
91. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009;9: 609-1606
92. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104: 2224-2234.
93. Grimshaw MJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanism. Eur J Immunol 2001;31:480-489.
94. Bosco MC, Reffo G, Puppo M, Varesio L. Hypoxia inhibits the expression of the CCR5 chemokine receptor in macrophages. Cell Immunol 2004;228:1-7.
95. Ostberg JR, Dayanc BE, Yuan M, Oflazoglu E, Repasky EA. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 2007;82:1322-1331.
96. Ostberg JR, Patel R, Repasky EA. Regulation of immune activity by mild (fever-range) whole body hyperthermia: Effects on epidermal Langerhans cells. Cell Stress Chaperones 2000;5:458-461.
97. Ostberg JR, Gellin C, Patel R, Repasky EA. Regulatory potential of fever-range whole body hyperthermia on Langerhans cells and lymphocytes in an antigendependent cellular immune response. J Immunol 2001;167:2666-2670.
98. Ostberg JR, Repasky EA. Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother 2006;55:292-298.
99. Dayanc BE, Beachy SH, Ostberg JR, Repasky EA. Dissecting the role of hyperthermia in natural killer cell mediated antitumor responses. Int J Hyperthermia 2008;24:41-56.
100. Ostberg JR, Kabingu E, Repasky EA. Thermal regulation of dendritic cell activation and migration from skin explants. Int J Hyperthermia 2003;19:520-533.
101. Guyton A, Hall J. Textbook of Medical Physiology, 11th edn. Elsevier Saunders Publishing; 2006.
102. Bard P, Woods J, Bleir R. The effects of cooling, heating and pyrogen on chronically decerebrate cats. Commun Behave Biol 1970;5:31.
103. Hardy JD. Physiology of temperature regulation. Physiol Rev 1961;41:521-606.
104. Charkoudian N. Skin blood flow in adult human thermoregulation: How it works, when it does not, and why. Mayo Clin Proc 2003;78:603-612.
105. Patapoutian A, Peier AM, Story GM, Viswanath V. ThermoTRP channels and beyond: Mechanisms of temperature sensation. Nat Rev Neurosci 2003;4:529-539.
106. Hammersen F, Endrich B, Messmer K. The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. Int J Microcirc Clin Exp 1985;4:31-43.
107. Oleson JR. Eugene Robertson Special Lecture. Hyperthermia from the clinic to the laboratory: A hypothesis. Int J Hyperthermia 1995;11:315-322.
108. Vujaskovic Z, Song CW. Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperthermia 2004;20:163-174.
109. Bicher HI, Hetzel FW, Sandhu TS, Frinak S, Vaupel P, O'Hara MD, O'Brien T. Effects of hyperthermia on normal and tumor microenvironment. Radiology 1980;137: 523-530.
110. Tanaka K, Hasegawa T, Murata T, Sawada S, Akagi K. Effects of hyperthermia combined with radiation on normal and tumor microcirculation. Proceedings of the International Conference on Cancer Therapy by Hyperthermia Radiation and Drugs. Tokyo: Mag Bros; 1982. pp 95-109.
111. Vaupel P, Muller-Klieser W, Otte J, Manz R. Impact of various thermal doses on the oxygenation and blood flow in malignant tumors upon localized hyperthermia. Adv Exp Med Biol 1984;169:621-629.
112. Vaupel P, Kallinowski F. Physiological effects of hyperthermia. Recent Results Cancer Res 1987;104:71-109.
113. Steen RG, Graham MM. 31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: Perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU. NMR Biomed 1991;4:117-124.
114. Song CW, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin Oncol 1997;24:626-632.
115. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Dodge RK, Charles HC, Samulski TV, Prosnitz LR, Dewhirst MW. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996;56: 5347-5350.
116. Song CW, Shakil A, Osborn JL, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia 1996;12:367-373. (Pubitemid 26158699)
117. Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001;155:515-528.
118. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009;28:3949-3959.
119. Okajima K, Griffin RJ, Iwata K, Shakil A, Song CW. Tumor oxygenation after mild-temperature hyperthermia in combination with carbogen breathing: Dependence on heat dose and tumor type. Radiat Res 1998;149:294-299.
120. Durand RE. Effects of hyperthermia on the cycling, noncycling, and hypoxic cells of irradiated and unirradiated multicell spheroids. Radiat Res 1978;75:373-384.
121. Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985;1:305-319.
122. Song CW, Lin JC, Chelstrom LM, Levitt SH. The kinetics of vascular thermotolerance in SCK tumors of A/J mice. Int J Radiat Oncol Biol Phys 1989;17:799-802.
123. Song CW, Patten MS, Chelstrom LM, Rhee JG, Levitt SH. Effect of multiple heatings on the blood flow in RIF-1 tumours, skin and muscle of C3H mice. Int J Hyperthermia 1987;3:535-545.
124. Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC, MacFall JR, Brizel DM, Meyer RE, Prescott DM, et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000;46:179-185.
125. Olch AJ, Kaiser LR, Silberman AW, Storm FK, Graham LS, Morton DL. Blood flow in human tumors during hyperthermia therapy: Demonstration of vasoregulation and an applicable physiological model. J Surg Oncol 1983;23:125-132.
126. Nah BS, Choi IB, Oh WY, Osborn JL, Song CW. Vascular thermal adaptation in tumors and normal tissue in rats. Int J Radiat Oncol Biol Phys 1996;35:95-101.
127. Xu Y, Choi J, Hylander B, Sen A, Evans SS, Kraybill WG, Repasky EA. Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin. Int J Hyperthermia 2007;23:513-527.